Intellia Therapeutics
NTLA
164 hedge funds and large institutions have $1.13B invested in Intellia Therapeutics in 2020 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 58 increasing their positions, 32 reducing their positions, and 19 closing their positions.
126% more call options, than puts
Call options by funds: $5.7M | Put options by funds: $2.52M
126% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 19
98% more capital invested
Capital invested by funds: $569M → $1.13B (+$558M)
81% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 32
17% more funds holding
Funds holding: 140 → 164 (+24)
2.78% more ownership
Funds ownership: 92.06% → 94.85% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23M |
| 2 |
BlackRock
New York
|
+$21.4M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$19.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$15.4M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$15.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.59M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.26M |
| 5 |
O
OrbiMed
New York
|
-$2.12M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Walleye Capital
New York
| – | -$18K | -1,485 | Closed |
|
|
SPIA
177
Steward Partners Investment Advisory
New York
| – | -$4K | -400 | Closed |
|
|
GI
178
Gradient Investments
Arden Hills,
Minnesota
| – | -$2K | -162 | Closed |
|
|
AA
179
Advisory Alpha
Holland,
Michigan
| – | -$1.42K | -100 | Closed |
|
|
NFG
180
Next Financial Group
Houston,
Texas
| – | -$1K | -100 | Closed |
|
|
EI
181
Ellevest Inc
New York
| – | -$51 | -3 | -14% |
|
NTLA Hedge Fund Activity: Q2 2020 in Review
164 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2020, worth a combined $1.13B — up 98% from $569M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new NTLA positions and 19 closed out — a net gain of 24 holders — while 58 added to existing stakes and 32 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $23M. The largest seller was Nikko Asset Management Americas, cutting an estimated $15.4M.
- 164 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2020, up from 140 in Q1 2020.
- Funds reported $1.13B of Intellia Therapeutics stock for Q2 2020, up 98% quarter-over-quarter.
- 43 funds opened new Intellia Therapeutics positions in Q2 2020 and 19 closed out, a net change of +24 holders.
- The largest Intellia Therapeutics buyer in Q2 2020 was T. Rowe Price Associates, an estimated $23M added.
- The largest Intellia Therapeutics seller in Q2 2020 was Nikko Asset Management Americas, an estimated $15.4M sold.
Based on aggregated 13F filings for Q2 2020.